JUNS JUPITER NEUROSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1679628 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-86.1%
TTM EPS YoY71.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-673.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets171.6%
Debt / equity—
Current ratio0.49x
Interest coverage-39.17x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-253.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13,942 | $24,245 | $18,652 | — | — | — | $0 | — |
| Cost of revenue | $4,334 | $3,181 | $4,362 | — | — | — | — | — |
| Gross profit | $9,608 | $21,064 | $14,290 | — | — | — | — | — |
| R&D expense | $3.89M | $600,353 | $411,049 | $43,684 | $816,697 | $759,448 | $466,745 | $201,005 |
| SG&A expense | $1.91M | $2.16M | $1.57M | $2.78M | $1.48M | $1.51M | $1.07M | $1.26M |
| Operating income | -$5.80M | -$2.74M | -$1.96M | -$2.81M | -$2.30M | -$2.26M | -$1.54M | -$1.46M |
| Interest expense | $68,098 | $90,618 | $118,644 | $62,463 | $1,193 | $1,135 | $1,229 | $30,545 |
| Net income | -$7.22M | -$2.27M | -$2.06M | -$2.58M | -$2.29M | -$2.25M | -$1.53M | -$1.53M |
| EPS (basic) | -7.42 | -4.08 | -0.06 | — | -5.04 | -5.09 | -0.05 | — |
| EPS (diluted) | -7.42 | -4.08 | -0.06 | — | -5.04 | -5.09 | -0.05 | — |
| Weighted avg. shares (diluted) | 973,633 | 557,567 | 35.26M | — | 453,865 | 442,413 | 33.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $300,623 | $1.52M | $2.36M | $3.79M | $723,797 | $1.88M | $2.71M | $3.77M |
| Receivables | — | $10,241 | — | $2,637 | — | — | — | — |
| Inventory | $130,957 | $135,290 | $148,068 | $159,790 | — | — | — | — |
| Current assets | $1.26M | $2.55M | $3.41M | $4.82M | $1.63M | $2.82M | $3.61M | $4.65M |
| Total assets | $1.62M | $3.72M | $3.95M | $5.56M | $2.58M | $3.97M | $4.96M | $6.20M |
| Current liabilities | $2.59M | $3.88M | $6.73M | $7.40M | $2.52M | $2.63M | $1.89M | $2.01M |
| Total liabilities | $2.79M | $4.08M | $6.73M | $7.40M | $2.52M | $2.63M | $1.90M | $2.03M |
| Shareholders' equity | -$1.16M | -$365,966 | -$2.78M | -$1.83M | $57,417 | $1.34M | $3.06M | $4.17M |
| Shares outstanding | 1.32M | 664,670 | 36.28M | 459,286 | 34.29M | 34.83M | 33.10M | 33.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.72M | -$2.29M | -$1.43M | -$2.37M | -$1.15M | -$828,222 | -$1.06M | -$3.70M |
| Financing cash flow | $1.50M | $1.45M | $5,507 | — | — | — | — | $7.47M |
| Stock-based compensation | $551,874 | $490,997 | $500,992 | $463,241 | $1.07M | $462,488 | $421,454 | $1.01M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.